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Abstract
Backgroud: The Piper laetispicum C.DC. (Piperaceae) is a traditionally used herb in China for invigorating circulation
and reducing stasis, detumescence and analgesia, which is distributed in the southern part of China and the
southeastern part of Asia. Previous studies demonstrated that the ethyl acetate extract (EAE-P) of P. laetispicum
possesses a significant antidepressant-like effect at doses higher than 60 mg/kg in Kunming (KM) mice, and this
effect was not due to an increase in locomotive activity.
Methods: To research this mechanism, in the present study, the chronic unpredictable mild stress (CUMS) model in
Sprague–Dawley rats was used to further elucidate behavioral changes and corresponding changes in inflammatory
cytokines (TNF-α, IL-6, IL-10), apoptosis cytokines (P53, Bax, Bcl2, caspase-3) and neurotrophin (BDNF) in the
hippocampus of EAE-P treatment animals.
Results and conclusions: The results suggest that EAE-P is beneficial to the behavioral outcome of the CUMS model
animals, and decreased amounts of inflammatory cytokine IL-6 contributed to the antidepressant-like activation of
EAE-P in every dosage group (15, 30, 60 mg/kg). In the low dosage group, down-regulated apoptosis cytokine p53 is
associated with EAE-P effect, but it is inflammatory cytokine TNF-α that is related to the effect of EAE-P in the high
dosage group. Meanwhile, the P53-dependent antiapoptotic effect of EAE-P may not be through Bcl-2 and Bax
modulation. Furthermore, EAE-P showed up-regulated expression of brain-derived neurotrophic factor (BDNF) mRNA
and down-regulated apoptosis cytokine caspase-3 mRNA, which was the same change tendency as with Fluoxetine.
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Background
Depression is one of the most burdensome diseases,
usually associated with acute and persistent symptoms
leading to life quality impairment [1]. Extensive studies
of herbal medicines potentially useful in the treatment
of depression have been conducted. Many of them have
been shown to have high efficacy and safety, such as
Hypericum perforatum (St. John’s wort), Panax ginseng,
Piper methysticum, Paullinia cupana var. sorbilis
(Guaraná) and Chaihu-Shugan-San, etc. [2–6].
The Piper laetispicum C.DC. (Piperaceae) is an en-
demic, climbing, glabrous plant distributed in the
southern part of China and the southeastern part of
Asia where it is popularly known as Xiao Chang-feng,
Shan Hu-jiao, and Ye Hu-jiao. It is traditionally used
for invigorating circulation and reducing stasis, detu-
mescence and analgesia in China [7]. Laetispicine
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(N-isobutyl- (3,4-methylendioxyphenyl)-2E, 4E, 9E-
undecatrienoamide) was previously isolated and re-
ported for its exertion of antidepressant activity and
antinociceptive effects in mice [8]. We further dem-
onstrated that the ethyl acetate extract of P. laetispi-
cum (EAE-P) possesses a significantly antidepressant-
like effect at doses higher than 60 mg/kg in KM
mice and proved that this was not due to an in-
crease in locomotive activity [9].
In this present study, the chronic unpredictable mild
stress (CUMS) model in Sprague -Dawley rats was used
to further elucidate the antidepressant-like effects and
mechanism of EAE-P. CUMS, the most promising ro-
dent model for depression, is further supported and
widely used for preclinical testing and screening of anti-
depressants [10–12]. In the CUMS model, animals are
subjected to a variety of mild stressors, which mimic
chronic stressful life events, presented intermittently for
prolonged periods of time, and result in a behavioral def-
icit anhedonia, a core symptom of human depression
[10]. Furthermore, since the hippocampus is critical for
stress, learning and memory processes in depression and
in the antidepressant response to pharmaco therapy
[13], the corresponding changes in inflammatory cyto-
kines (TNF-α, IL-6, IL-10), apoptosis cytokines (P53,
Bax, Bcl2, caspase-3) and neurotrophin (BDNF) in the




Adult male Sprague–Dawley rats weighing between 180
and 200 g were purchased from the Department of
Experimental Animal Center of Fudan University. Rats
were housed under a normal 12 h light/dark cycle with
lights on at 7 a.m. Tap water and standard food pellets
were available ad libitum. Ambient temperature and rela-
tive humidity were maintained at 22–25 °C and 55 ± 10 %,
respectively. Prior to the test procedure, rats were accli-
matized the laboratory for seven days. The experimental
procedures were conducted in compliance with the
National Institutes of Health Guide for Care and Use
of the laboratory animals and were approved by the
Local Bioethics Committee (School of Pharmacy, Fudan
University, China; document number: SYXK2007-002).
Every effort was made to minimize the number and suffer-
ing of the animals used.
After a seven-day environmental adaptation, 54 ani-
mals were randomly divided into six groups: non-
stressed control group (abbreviation: Control); 20 mg/kg
fluoxetine group (abbreviation: Fluoxetine); model group
(abbreviation: Model); 15 mg/kg EAE-P group (abbrevi-
ation: 15 mg/kg); 30 mg/kg EAE-P group (abbreviation:
30 mg/kg); and 60 mg/kg EAE-P group (abbreviation:
60 mg/kg). Each group’s baseline of 1 % sucrose prefer-
ence, motor activity, body weight, and food consumption
were measured. There were no significant differences
amongst the groups. The results are shown in Table 1.
The control rats were kept undisturbed in their home
cages during the entire period of treatment, receiving
only ordinary facility care with daily support of food and
water, except for the sucrose intake test. The animals in
other groups were fed separately in single cages.
Chronic unpredictable mild stress (CUMS) mode
The chronic unpredictable mild stress protocol was
adapted from Gamaro et al. [14]. The eight-week CUMS
paradigm’s first 28 days are shown in Table 2; the follow-
ing days repeat it. One of the stressors was used each day
and only interrupted by the sucrose preference test. This
paradigm was used for the animals in the Fluoxetine,
Model, 15 mg/kg group, 30 mg/kg group and 60 mg/kg
group.
Plant material
The stems of P. laetispicum were collected in 2006, from
Hainan Province, China. The plant was identified by
Professor Sheng-li Pan, School of Pharmacy, Fudan
University, where a voucher specimen (No.060812) of the
plant material has been deposited for further reference.
Before use, the dried stems of P. laetispicum were
stored at −20 °C in freezer.
Extract and drugs
The dried stems of P. laetispicum (20 kg) were powdered
and percolated with 95 % EtOH (Ethyl alcohol), and the
solution was concentrated under reduced pressure to
give crude extract (1510 g). The ethyl acetate extract
(EAE-P) was obtained following the methods published
by our group [9] [15]. The HPLC profile was the same
with Xie et al. [9]. And the content of four major com-
ponents in EAE-P – Chingchingenamide (1.24 mg/g),
Laetispiamide A (12.67 mg/g), Laetispiamide B (1.25 mg/g)
and Laetispicine (9.65 mg/g) - were approached.
The EAE-P was kept refrigerated at + 4 °C and sus-
pended in a solution of 2 % Tween-80 in saline by
sonication with an ultrasonic cleaner (SK2200H,
Shanghai KUDOS Ultrasonics instrument Co., Ltd
(Shanghai, China)) less than 60 °C. The 2 % Tween-80
in saline also served as a solution control. Pharmaco-
logical screenings were performed and administered in
doses of 15, 30 and 60 mg/kg body weight. All dosages
were expressed as milligrams per kilogram body
weight.
Fluoxetine-HCl, which purity was 98 %, was used in a
concentration of 20 mg/kg body weight and prepared
fresh on the day of administration in solution (2 %
Tween-80 suspension in saline).
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95 % EtOH, ethyl acetate, Tween-80 were purchased
from Sinopharm Chemical Reagent Co., Ltd (Shanghai,
China). Saline was from Shanghai Zhongxi Pharma-
ceutical Co., Ltd (Shanghai, China). Fluoxetine-HCl
was from Cyber- Hubei Cyber Pharmaceutical Co., Ltd.
(Wuhan, China).
Sucrose preference test
A sucrose preference test was employed in order to
determine anhedonia, one of the core symptoms of
major depression in humans [11]. After environmental
adaptation, rats were trained to consume 1 % (w/v)
sucrose solution. Then the rats were simultaneously pre-
sented with 1 % sucrose solution and fresh water for 1 h
after 23 h of food and water deprivation, as reported
previously [16]. Sucrose preference (SP) was calculated
according to the following formula: SP = sucrose intake/
(sucrose intake + water intake) × 100 %. The sucrose
preference test was performed each week and measured
between 9 a.m. and 10 a.m. During this period, the ani-
mals were stressed daily, and the food and water were
removed the night before the test.
Open field test
The open field test method used in the present study
was similar to that described previously by Kim [6]. The
apparatus was a square arena (diameter: 80 cm; height:
40 cm) with a light source of 120 lx, which was demar-
cated into 25 equal areas. The score locomotion (num-
ber of line crossings), rearing frequencies (number of
times an animal stood on its hind legs) and grooming
time were recorded.
Food utilization rate
Intake of food was measured by weighing the remaining
food between 9 a.m. and 10 a.m. every day. Body weight
was recorded at the end of each week. The food
utilization rate (FUR) was calculated according to the
following formula: FUR = body weight gain per week (g)/
food-intake (g) per week × 100 % [17, 18].
Blood collection and serum cytokine assay
After the last treatment of drugs, approximately 5 mL
of blood was collected from the rat tail. Serum cyto-
kine levels of BDNF were measured using the Rat
Table 1 The baseline of sucrose solution consumption, motor activity, body weight and food consumption
Groups 1 % Sucrose solution
consumption (%)









control 76.44 ± 2.19 137.78 ± 11.28 22.11 ± 2.71 10.96 ± 2.02 263.17 ± 4.45 27.90 ± 1.31
Fluoxetine 77.46 ± 2.24 135.81 ± 7.64 26.00 ± 2.10 12.19 ± 4.01 266.83 ± 3.18 28.20 ± 1.72
model 77.37 ± 2.29 120.72 ± 8.97 23.00 ± 2.39 13.88 ± 1.97 256.08 ± 6.36 33.00 ± 0.47
15 mg/kg 78.68 ± 2.48 138.69 ± 11.00 26.14 ± 3.62 10.84 ± 1.85 258.14 ± 7.74 31.74 ± 1.17
30 mg/kg 76.70 ± 3.90 119.42 ± 17.12 20.17 ± 3.11 16.28 ± 5.23 251.35 ± 4.88 30.86 ± 1.44
60 mg/kg 78.40 ± 3.47 135.19 ± 8.54 28.29 ± 4.17 17.58 ± 1.65 265.27 ± 3.51 28.17 ± 1.65
Data are expressed as mean ± S.E.M.(n = 8–9). The statistical analysis was performed by analysis of variance (ANOVA) followed by Bonferroni’s test
Table 2 The unpredictable chronic mild stress protocol
1 Light during the night 15 24 h of damp sawdust
2 5 min swimming at 4 °C 16 15 min Shaker rocking 1 time/second
3 24 h of food deprivation 17 Light during the night
4 24 h of water deprivation 18 24 h of water deprivation
5 Light during the night 19 1 min clipping tail
6 15 min shaker rocking 1 time/second 20 2 h of restraint
7 24 h of food deprivation 21 5 min swimming at 45 °C
8 1 min clipping tail 22 2 h of restraint
9 2 h of restraint 23 1 min clipping tail
10 5 min swimming at 45 °C 24 24 h of damp sawdust
11 5 min swimming at 4 °C 25 24 h of water deprivation
12 5 min swimming at 45 °C 26 5 min swimming at 4 °C
13 15 min shaker rocking 1 time/second 27 24 h of damp sawdust
14 24 h of food deprivation 28 5 min swimming at 4 °C
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BDNF (Brain-Derived Neurotrophic Factor) ELISA Kit
(Xitang, Shanghai Xitang Technology Co., Ltd,
Shanghai, China) and analyzed using Multiskan MK3
(Thermo, Thermo Scientific, USA). Serum from each
animal was assayed in duplicate per manufacturer’s
instructions.
Real-time PCR
Total RNA was extracted from hippocampi using TRIzol
reagent and assessed for quantity and integrity using
agarose gel electrophoresis and Eppendorf Biophotometer
Plus (Eppendorf, New Brunswick, CA). Total mRNA
(1 μg) was reverse transcribed using PrimeScript@ 1-st
Strand cDNA Synthesis Kit (TaKaRa, TAKARA Biotech-
nology (Dalian) Co., Ltd., Dalian, China) according to the
manufacturer’s manual.
Real-time PCR was performed on a fluorescence ration
PCR instrument (BioNeer, Korea) using SYBR@ Premix
Ex TaqTM II (TaKaRa, TAKARA Biotechnology (Dalian)
Co., Ltd., Dalian, China). Target cDNA (TNF-α, IL-6,
IL-10, P53, BDNF, Bax, Bcl2, caspase-3) and endogen-
ous control cDNA (actin) were amplified under the fol-
lowing conditions: 94 °C for 4 min, 35 cycles at 94 °C
for 20 s, 60 °C for 30 s and 72 °C for 30 s. Relative
quantitative (RQ) measurements of target gene levels
were performed using the ΔΔCt method, where Ct is
the threshold concentration [19]. The oligonucleotides
used as primers are shown in Table 3.
Western blot analysis
For immunoblotting studies, hippocampal total pro-
tein was prepared by homogenization in lysis buffer
containing 20 mM Tris–HCl (pH 7.5), 150 mM NaCl,
1 mM EDTA, and 0.1 % sodium dodecyl-sulfate
(SDS). The proteins were purified, resolved and elec-
trotransferred as reported previously [20]. All blots
were re-probed with β-actin antibody (1:4000 dilu-
tion, mouse monoclonal, Sigma, purchased from
Sinopharm Chemical Reagent Co., Ltd (Shanghai,
China)) as an internal control. Immunoreactive bands
were revealed by an enhanced chemiluminescence kit
(ECL Amersham from GE Healthcare) and detected
using X-ray films. The immunoblot films were scanned,
and the digitalized images analyzed with Gel-Pro Analyzer
software.
Statistical analysis of data
SPSS 15.0 was used for statistical analysis. Statistical
significance between groups was performed by the
application of analysis of variance ANOVA followed
by Bonferroni’s test. Data obtained were expressed
as mean ± standard error of the mean (S.E.M.). And
P-values less than 0.05 (p < 0.05) were used as the
significant level.
Results and discussion
Effects of EAE-P on Behavioral Tests in the CUMS-treated
rats
The sucrose preference test was used to determine the
animals’ depressive state [11]. As shown in Fig. 1, the
baseline sucrose preference index was 76.44–78.68 %
(the numerical value display in Table 1). At the end of the
third week, significant differences were observed between
the control and model groups, which are the key indicator
of successful implementation of the CUMS model. After
the administration of different concentrations of EAE-P
for five weeks, the sucrose preferences of the 15 mg/kg,
30 mg/kg and 60 mg/kg groups were significantly higher
than the model group (p < 0.001). Meanwhile, treatment
with Fluoxetine also significantly increased the percentage
of sucrose consumption as compared to the control group
(p < 0.001), but this result needed six weeks of administra-
tion, one week longer than EAE-P.
Nonetheless, at the second week of Fluoxetine and the
fifth week of 30 mg/kg EAE-P, the sucrose preference
was significantly lower than the control group (p < 0.05
and p < 0.001). This was very interesting.
The Open Field Test (OFT) is commonly used to in-
vestigate locomotor activity, exploratory and depressive-
like behaviors in experimental animals [21]. The times of
score locomotion and rearing frequencies, and the sec-
onds of grooming time were measured during the OFT
at the end of the CUMS procedure. These details are
shown in Table 4. After eight weeks, no significant dif-
ferences were discovered. This suggests the EAE-P given
in a subchronic treatment regime was beneficial for the
behavioral outcome, which was not due to an increase in
locomotive activity.
For the Food Utilization Rate (FUR), as shown in Fig. 2,
there were no significant differences amongst the groups
during the first stressful week of the CUMS procedure. Dur-
ing the second week, the FUR of the model group and all of
the EAE-P groups increased, and demonstrated significant
differences compared to the control group (p < 0.001). At
the end of the third week, the FUR was close to the control
group, except for the Fluoxetine group, which was signifi-
cantly higher than the model and control groups (p < 0.001).
In the following week, the FUR of the 30 mg/kg group
abruptly increased (compared to the other groups (p <
0.001)). At the next week (the fifth week), the FUR of
the control group was unexpectedly lower than the
model (p < 0.01) and 15 mg/kg (p < 0.05) groups. In the
last three weeks, the FUR of the control group was signifi-
cantly higher than the model and all of the EAE-P groups.
Meanwhile, the Fluoxetine group was significantly
lower than the model, 15 mg/kg or 60 mg/kg EAE-P
groups at the second and the last three weeks, and sig-
nificantly lower than the 30 mg/kg group at the fourth
and seventh week. The details of comparison between
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Fig. 1 Effects of EAE-P on sucrose preference in the CUMS-treated rats. Results are expressed as mean ± S.E.M. (n = 7–9). Statistical analysis was
performed by analysis of variance (ANOVA) followed by Bonferroni’s test.▲ P <0.05,▲▲P <0.01, **P <0.01,▲▲▲P <0.001 and ***P <0.001
compared with model
Table 3 The oligonucleotides used as primers
Gene Primer name Sequence of primer Target length
tnfα rTNFaF CTTCTCATTCCTGCTCGTGG 140 bp
rTNFaR ATCTGAGTGTGAGGGTCTGGG
IL-6 rIL6F AAGCCAGAGTCATTCAGAGCAA 160 bp
rIL6R TGGATGGTCTTGGTCCTTAGC
IL-10 rIL10F CCTGGTAGAAGTGATGCCCC 163 bp
rIL10R ATTCTTCACCTGCTCCACTGC
AIF rAIFF CTGAGAAAGGAAATATGGGGAA 138 bp
rAIFR TGAGTAACTTGCCACCGCTG
P53 rP53F GGAAGGAAATCCGTATGCTGA 177 bp
rP53R GTGATGATGGTAAGGATGGGC
Bax rBaxF CCCGAGAGGTCTTCTTCCG 167 bp
rBaxR GAAGTCCAGTGTCCAGCCCA
caspase-3 rcaspase-3 F CGAAACTCTTCATCATTCAGGC 129 bp
rcaspase-3R AGTAAGCATACAGGAAGTCGGC
Bdnf rBdnfF CAGCGGCAGATAAAAAGACTG 187 bp
rBdnfR GTAGTTCGGCATTGCGAGTTC
TrkB rTrkBF TATGAAGACTGGACCACGCC 167 bp
rTrkBR AGAAGCAGCATCACCAGCAG
CREB rCREBF AGACCACTGATGGACAGCAGAT 150 bp
rCREBR TAGGAAGTGCTGGGGAGGAC
Bcl-2 rBcl-2 F GTGAACTGGGGGAGGATTGT 167 bp
rBcl-2R GCATCCCAGCCTCCGTTA
actin rat actin f CCCATCTATGAGGGTTACGC 150 bp
rat actin r TTTAATGTCACGCACGATTTC
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the Fluoxetine group and EAE-P groups are shown in
Table 5, which demonstrates that EAE-P may be more
beneficial to the FUR than Fluoxetine. The variation ten-
dency is shown in Fig. 3.
In summary, EAE-P given in a subchronic treatment
regime was beneficial to the behavioral outcome in an
animal model of CUMS which induced depression-like
behavioral changes.
Effects of EAE-P on the inflammatory cytokines in
CUMS-treated rats
In healthy individuals, there is a regulated balance be-
tween pro- and anti-inflammatory cytokines. Altered
inflammatory cytokine profiles are often observed in de-
pressed individuals [22].
The tumor necrosis factor-alpha (TNF-α), which is a
pro-inflammatory key signaling molecule, might con-
tribute to the pathogenesis of depression because
plasma levels of TNF-α and its soluble receptors have
been found to be elevated in acutely depressed pa-
tients [23], and experimental stimulation of TNF-α
production leads to depression-like emotional and
cognitive disturbances in humans [24]. In the present
study, the mRNA and protein expression level of
TNF-α in the hippocampus was measured. Results
show significantly higher in depressed subjects compared
Table 4 Effects of EAE-P on the open field parameters recorded for 6 min in rats
Groups Score Locomotion(times) Rearing Frequencies(times) Grooming Time(seconds)
Begin After Begin After Begin After
control 137.78 ± 11.28 121.00 ± 12.41 22.11 ± 2.71 16.78 ± 2.11 10.96 ± 2.02 18.83 ± 5.04
Fluoxetine 135.81 ± 7.64 97.75 ± 16.71 26.00 ± 2.10 13.50 ± 3.15 12.19 ± 4.01 40.47 ± 8.82
model 120.72 ± 8.97 100.33 ± 14.18 23.00 ± 2.39 25.33 ± 4.37 13.88 ± 1.97 21.60 ± 5.55
15 mg/kg 138.69 ± 11.00 126.50 ± 15.02 26.14 ± 3.62 17.88 ± 2.96 10.84 ± 1.85 14.67 ± 6.12
30 mg/kg 119.42 ± 17.12 99.71 ± 13.20 20.17 ± 3.11 20.71 ± 2.62 16.28 ± 5.23 25.99 ± 5.74
60 mg/kg 135.19 ± 8.54 128.75 ± 16.07 28.29 ± 4.17 24.50 ± 3.18 17.58 ± 1.65 21.33 ± 4.15
Data are expressed as mean ± S.E.M. (n = 8–9). The statistical analysis was performed by analysis of variance (ANOVA) followed by Bonferroni’s test
Fig. 2 Effects of EAE-P on the food utilization rate (FUR) in the CUMS-treated rats. Results are expressed as mean ± S.E.M. (n = 7–9). Statistical
analysis was performed by analysis of variance (ANOVA) followed by Bonferroni’s test. ▲▲P <0.01, **P <0.01,▲▲▲P <0.001 and ***P <0.001
compared with model
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to controls (p < 0.001) (Fig. 4). Compared with the
model group, Fluoxetine markedly (p < 0.001) re-
duced TNF-α mRNA and protein in the hippocam-
pus. EAE-P treatment at 60 mg/kg also reduced the
mRNA and protein (p < 0.001). However, EAE-P
treatment at 30 mg/kg only reduced the protein ex-
pression but not mRNA. This revealed that a high
concentration of EAE-P can effectively reverse the
action of TNF-α.
In recent years, elevated interleukin (IL)-6 has been re-
ported as a biomarker of depression [25]. IL-10 has been
reported to play a role in regulating hypotha-lamic-
pituitary-adrenal (HPA) axis homeostasis by suppressing
adrenocorticotropic hormone-induced steroid produc-
tion, and diminished IL-10 expression can affect HPA
hyperactivity and glucocorticoid resistance seen in de-
pressed patients [26]. In addition, the literature describes
concurrent increases in IL-6 and decreases in IL-10 in
individuals suffering from major depression. It is hy-
pothesized that higher levels of depressive symptoms
would be associated with lower IL-10 and higher IL-6
concentrations, as well as higher IL-6/IL-10 ratios. Also,
as shown in Fig. 4, depressed subjects expressed signifi-
cantly higher IL-6 mRNA and protein expression levels,
lower IL-10 and significantly higher IL-6/IL-10 ratios
compared to controls. Treatment at different concentra-
tions of EAE-P, compared with the model group, showed
significantly lower IL-6 (mRNA: 15 mg/kg, p < 0.001;
30 mg/kg, p < 0.05; 60 mg/kg, p < 0.01. Protein: 15 mg/kg,
p < 0.001; 30 mg/kg and 60 mg/kg, p < 0.01), no signifi-
cant change in IL-10 and partially significantly lower
IL-6/IL-10 ratios (mRNA: 15 mg/kg, p < 0.001. Protein:
15 mg/kg, p < 0.05; 30 mg/kg and 60 mg/kg, p < 0.01).
Meanwhile, the Fluoxetine group revealed significantly
lower IL-6, significantly higher IL-10 and significantly
lower IL-6/IL-10 ratios. These results indicate that the
antidepressant-like activation of EAE-P is associated
with inflammatory cytokine IL-6 and even IL-6/IL-10
ratios but not IL-10. That is different than the response
to Fluoxetine.
Table 5 Comparison of food utilization rate (FUR) between Fluoxetine group and EAE-P groups
Groups Week 1 Week 2 Week 3 Week 4
Fluoxetine 11.03 ± 3.14 14.95 ± 4.42 21.39 ± 1.47 10.45 ± 0.88
15 mg/kg 11.44 ± 1.49 27.78 ± 3.99 ★ 15.13 ± 1.37▲▲ 17.07 ± 1.16
30 mg/kg 13.91 ± 2.55 19.74 ± 1.06 12.01 ± 1.47▲▲▲ 30.88 ± 0.91★★★
60 mg/kg 8.53 ± 2.29 27.36 ± 1.69★★ 12.61 ± 1.00▲▲▲ 16.69 ± 1.37
Groups Week 5 Week 6 Week 7 Week8
Fluoxetine 13.02 ± 1.09 5.70 ± 1.56 −3.99 ± 0.76 −3.37 ± 0.52
15 mg/kg 16.56 ± 0.84 18.52 ± 0.83★★★ 5.15 ± 0.96★★★ 2.49 ± 0.89★
30 mg/kg 13.39 ± 1.19 12.64 ± 1.29 5.92 ± 1.36★★★ −0.17 ± 0.54
60 mg/kg 16.41 ± 0.56 14.53 ± 1.68 ★ 9.37 ± 1.75★★★ 4.71 ± 0.72★★
Results are expressed as mean ± S.E.M. (n = 7–9). Statistical analysis was performed by analysis of variance (ANOVA) followed by Bonferroni’s test. ★★★ means the
result is higher than Fluoxetine group. ▲▲▲means the result is lower than Fluoxetine group. ▲ p < 0.05,★p < 0.05, ▲▲P < 0.01, ★★P < 0.01, ▲▲▲P < 0.001
and ★★★P < 0.001 compared with model
Fig. 3 Comparision of food utilization rate (FUR) variation tendency between Fluoxetine group and EAE-P groups
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Effects of EAE-P on apoptosis cytokines in CUMS-treated
rats
In addition to inflammatory cytokines, we also investi-
gated the effect of EAE-P on mRNA expression of four
apoptosis cytokines, because the apoptosis cytokines
have been demonstrated by in vivo imaging studies that
patients with major depressive disorders display reduced
hippocampal and prefrontal cortex volume [27]. These
structural alterations resulted from atrophy and loss of
neurons and glia [28]. Activation of apoptotic pathways
has been regarded as one of the most important way to
cause these structural alterations. P53 is the “gatekeeper”
of apoptosis. P53 activity is directed at its transcriptional
target Bax [29], or it translocates to mitochondria to
interact with Bcl-2 in a non-transcriptional way [30].
The caspase-dependent mitochondrial way is another
approach.
In this study, p53 mRNA was upregulated by the
CUMS treatment (Fig. 5). Fluoxetine and 15 mg/kg of
EAE-P decreased hippocampal p53 mRNA expression
(P < 0.001) when compared with the model group. This
suggests that EAE-P pretreatment may depress p53 to
inhibit apoptosis. The Real-Time PCR results of Bax and
Bcl-2 showed that pretreatment with EAE-P did not pro-
duce pharmacological effects (Fig. 5), with the exception
of Bcl-2 at 30 mg/kg. The influence of EAE-P on
caspase-3 (Fig. 5) was showed that Fluoxetine and all the
different concentrations of EAE-P markedly reduced
caspase-3 mRNA expression compared to the control
and model (P < 0.001), similar to the results obtained
with Fluoxetine. Nevertheless, there is no significant dif-
ference in caspase-3 levels between the control and
model. Further research is necessary to understand these
results.
Effects of EAE-P on the BDNF expression in CUMS-treated
rats
The neurotrophin brain-derived neurotrophic factor
(BDNF) is a member of the neurotrophin family and the
most wide spread growth factor in the brain. It has
diverse functions in the adult brain as a regulator of
neuronal survival, fast synaptic transmission and
activity-dependent synaptic plasticity [31]. Increasing
evidence indicates that BDNF may play a role in the
pathophysiology of depression and that antidepressants
may, in part, exert their effects through regulation of
BDNF. Decreased serum BDNF levels have been re-
ported in depressed patients in several clinical studies,
as has the fact that they can be normalized by anti-
depressant treatment [32]. Recent studies also have re-
ported no effects or even increased BDNF levels in the
hippocampus following exposure to chronic stress. It is
Fig. 4 Effects of EAE-P on the inflammatory cytokines (TNF-α, IT-6, IT-10 and IL-6/IL-10 ratios) in CUMS-treated rats. Results are expressed as
mean ± S.E.M.(n = 7-9). Statistical analysis was performed by analysis of variance (ANOVA) followed by Bonferroni’s test. * p < 0.05, ** p < 0.01,
*** p < 0.001 compared with model
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possible that the effects of stress on BDNF mRNA
expression in the hippocampus are dependent on sev-
eral factors such as the type of stressor, the intensity,
the duration, the frequency and the number of expo-
sures [33].
The levels of serum BDNF and the BDNF mRNA in
the hippocampus are presented in Fig. 6. Although the
level of serum BDNF and the BDNF mRNA expression
are decreased in the model group compared to the con-
trol group, there are no significant differences between
them. However, compared with the model group, Fluox-
etine markedly (p < 0.001) elevated BDNF mRNA in the
hippocampus. EAE-P treatment at 15 and 30 mg/kg also
elevated it (p < 0.05). It has been suggested that BDNF
levels may simply not correlate with depressive-like
behavior, and a clear correlation between serum and
brain BDNF levels still needs to be established. However,
Fluoxetine and EAE-P showed up-regulated expression
in this study, which needs a further research.
Conclusion
The results reveal that EAE-P is beneficial to the be-
havioral outcome of the CUMS model animals, which
was not due to an increase in locomotive activity. The
Fig. 5 Effects of EAE-P on apoptosis cytokines (p53, Bax, Bcl-2 and caspase-3) in CUMS-treated rats. Results are expressed as mean ± S.E.M.
(n = 7–9). Statistical analysis was performed by analysis of variance (ANOVA) followed by Bonferroni’s test. ** p < 0.01, *** p < 0.001 compared
with model
Fig. 6 Effects of EAE-P on Neurotrophin (BDNF) in CUMS-treated rats. Results are expressed as mean ± S.E.M. (n = 7–9). Statistical analysis was
performed by analysis of variance (ANOVA) followed by Bonferroni’s test. * p < 0.05, *** p < 0.001 compared with model
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decreased amounts of inflammatory cytokine IL-6 con-
tributed to the antidepressant-like activation of EAE-P
in every dosage group (15, 30, 60 mg/kg). However, in
the low dosage group, down-regulated apoptosis cyto-
kine p53 is associated with EAE-P effect, but it is in-
flammatory cytokine TNF-α that is related to the effect
of EAE-P in the high dosage group. These suggest that
the EAE-P needs to be subdivided for the further
mechanism research. Meanwhile, the P53-dependent
antiapoptotic effect of EAE-P may not be through Bcl-2
and Bax modulation.
Furthermore, EAE-P showed up-regulated expression
of brain-derived neurotrophic factor (BDNF) mRNA and
down-regulated apoptosis cytokine caspase-3 mRNA,
which was the same change tendency as with Fluoxetine,
although there is no significant differences between
model and control in Sprague–Dawley rats’ CUMS
mode.
Abbreviations
EAE-P: Ethyl acetate extract of P. laetispicum; CUMS: Chronic unpredictable
mild stress; OFT: Open field test; FUR: Food utilization rate; BDNF:
Brain-derived neurotrophic factor; SP: Sucrose preference.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
HX carried out the design of the study, performed the statistical analysis and
drafted the manuscript. DJ carried out the experimentation on animals. YK
participated in the animal experimentation and its design. XS participated in
the design of the study. Hongrui Liu participated in the statistical analysis. HS
participated in the animal and molecular experimentation. JC participated in
the animal and molecular experimentation. MY participated in the molecular
experimentation. JL approved the manuscript. SP participated in the design
of the study, checked and approved the manuscript. All authors read and
approved the final manuscript.
Acknowledgments
The study was supported and funded by the Ministry of Science and
Technology of the People’s Republic of China (No. 2009ZX09103-075);
Science Committee of Shanghai, China (No. 08DZ1971203); Pudong New
District of Shanghai, China (No. PW2008A-7); Beginning Teacher Scientific
Research Initial Funding of Fudan University, China. The authors wish to
acknowledge Jackie Kelley and Bonnie Watson for their helpful improvement
of the English language.
Author details
1School of Pharmacy, Fudan University, Shanghai 201203, China.
2Department of Pharmacognosy, College of Pharmacy, Jiamusi University,
Jiamusi 154007, China. 3Pharmaceutical Preparation Section, Punan Hospital,
Shanghai 200127, China.
Received: 25 September 2014 Accepted: 24 June 2015
References
1. Engel D, Zomkowski AE, Lieberknecht V, Rodrigues AL, Gabilan NH. Chronic
administration of duloxetine and mirtazapine downregulates proapoptotic
proteins and upregulates neurotrophin gene expression in the
hippocampus and cerebral cortex of mice. J Psychiatr Res. 2013;47:802–8.
2. Linde K, Berner MM, Kriston L. St John's wort for major depression.
Cochrane Database Syst Rev. 2008;8(4):CD000448.
3. Dang HX, Chen Y, Liu XM, Wang Q, Wang LW, Jia W, et al. Antidepressant
effects of ginseng total saponins in the forced swimming test and chronic
mild stress models of depression. Prog Neuro-Psychoph. 2009;33:1417–24.
4. Baum SS, Hill R, Rommelspacher H. Effect of kava extract and individual
kavapyrones on neurotransmitter levels in the nucleus accumbens of rats.
Prog Neuro-Psychoph. 1998;22:1105–20.
5. Mello JC, Klein T, Longhini R, Bruschi ML. Development and characterization
of microparticles from Paullinia cupana var. sorbilis (Guaraná) semipurified
extract produced by spray drying. Planta Med. 2013;79:PN61.
6. Kim SH, Han J, Seog DH, Chung JY, Kim N, Park YH, et al. Antidepressant
effect of Chaihu- Shugan-San extract and its constituents in rat models of
depression. Life Sci. 2005;76:1297–306.
7. Zhonghua Herbals Editorial Committee. Zhonghua Herbals. Shanghai:
Shanghai Science Technique Press; 1999. p. 433–4.
8. Yao CY, Wang J, Dong D, Qian FG, Xie J, Pan SL. Laetispicine, an amide
alkaloid from Piper laetispicum, presents antidepressant and antinociceptive
effects in mice. Phytomedicine. 2009;16:823–9.
9. Xie H, Yan MC, Jin D, Liu JJ, Yu M, Dong D, et al. Studies on antidepressant
and antinociceptive effects of ethyl acetate extract from Piper laetispicum
and structure - activity relationship of its amide alkaloids. Fitoterapia.
2011;82:1086–92.
10. Willner P, Towell A, Sampson D, Sophokleous S, Muscat R. Reduction of
sucrose preference by chronic unpredictable mild stress, and its
restoration by a tricyclic antidepressant. Psychopharmacology.
1987;93:358–64.
11. Bekris S, Antoniou S, Daskas S, Papadopoulou-Daifoti Z. Behavioral and
neurochemical effects induced by chronic mild stress applied to two
different rat strains. Behav Brain Res. 2005;161:45–59.
12. Li J, Zhou Y, Liu BB, Liu Q, Geng D, Weng L, et al. Nobiletin Ameliorates the
Deficits in Hippocampal BDNF, TrkB, and Synapsin I Induced by Chronic
Unpredictable Mild Stress. Evid-Based Compl Alt. 2013;Article ID 359682:1–11.
13. Campbell S, Macqueen G. The role of the hippocampus in the
pathophysiology of major depression. J Psychiatr Neurosci. 2004;29:417–26.
14. Gamaro GD, Prediger ME, Lopes J, Bassani MG, Dalmaz C. Fluoxetine alters
feeding behavior and leptin levels in chronically-stressed rats. Pharmacol
Biochem Behav. 2008;90:312–7.
15. Cai CC, Yan MC, Xie H, Pan SL. Simultaneous Determination of Ten Active
Components in 12 Chinese Piper Species by HPLC. Am J Chinese Med.
2011;39:1043–60.
16. Li LF, Lu J, Li XM, Xu CL, Yang J, Qu R, et al. Antidepressant-like effects of
the saponins extracted from Chaihu-jia-longgu-muli-tang in a rat
unpredictable chronic mild stress model. Fitoterapia. 2012;83:93–103.
17. Razzoli M, Domenici E, Carboni L, Rantamaki T, Lindholm J, E. Castrén E, et al. A
role for BDNF/TrkB signaling in behavioral and physiological consequences of
social defeat stress. Genes, Brain and Behavior. 2011;10:424–33.
18. Na XL, Liu XW, Chen WH. Effects of soybean isoflavone on body weight and
food utilization rate in ovariectomized rats. Journal of Hygiene Research.
2005;34:432-35.
19. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using
real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods.
2001;25:402–8.
20. Marcellino D, Roberts DCS, Navarro G, Filip M, Agnati L, Lluis C, et al.
Increase in A (2A) receptors in the nucleus accumbens after extended
cocaine self-administration and its disappearance after cocaine withdrawal.
Brain Res. 2007;1143:208–20.
21. Zhou YZ, Lu LL, Li ZF, Gao XX, Tian JS, Zhang LZ, et al. Antidepressant-like
effects of the fractions of Xiaoyaosan on rat model of chronic unpredictable
mild stress. J Ethnopharmacol. 2011;137:236–44.
22. Dantzer R, O’Connor JC, Lawson MA, Kelley KW. Inflammation-associated
depression: From serotonin to kynurenine. Psychoneuroendocrinology.
2011;36:426–36.
23. Himmerich H, Fulda S, Linseisen J, Seiler H, Wolfram G, Himmerich S, et al.
Depression, comorbidities and the TNF-alpha system. Eur Psychiat. 2008;23:421–9.
24. Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A, et al.
Cytokine-associated emotional and cognitive disturbances in humans. Arch
Gen Psychiat. 2001;58:445–52.
25. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-
analysis of cytokines in major depression. Biol Psychiatry. 2010;67:446–57.
26. Voorhees JL, Tarr AJ, Wohleb ES, Godbout JP, Mo XK, Sheridan JF, et al.
Prolonged Restraint Stress Increases IL-6, Reduces IL-10, and Causes
Persistent Depressive-Like Behavior That Is Reversed by Recombinant IL-10.
PLOS ONE. 2013;8:e58488.
27. Bremner JD. Structural changes in the brain in depression and relationship
to symptom recurrence. CNS Spectrums. 2002;7:129–130. 135–139.
Xie et al. BMC Complementary and Alternative Medicine  (2015) 15:240 Page 10 of 11
28. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature.
2008;455:894–902.
29. Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler
M, et al. Direct activation of Bax by p53 mediates mitochondrial membrane
permeabilization and apoptosis. Science. 2004;303:1010–4.
30. Vaseva AV, Moll UM. The mitochondrial p53 pathway. Biochim Biophys Acta.
2009;1787:414–20.
31. Bramham CR, Messaoudi E. BDNF function in adult synaptic plasticity: the
synaptic consolidation hypothesis. Prog Neurobiol. 2005;76:99–125.
32. Brunoni AR, Lopes M, Fregni F. A systematic review and meta-analysis of
clinical studies on major depression and BDNF levels: implications for the
role of neuroplasticity in depression. Int J Neuropsychoph. 2008;11:1169–80.
33. Larsen MH, Mikkelsen JD, Hay-Schmidt A, Sandi C. Regulation of brain-derived
neurotrophic factor (BDNF) in the chronic unpredictable stress rat model
and the effects of chronic antidepressant treatment. J Psychiatr Res.
2010;44:808–16.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Xie et al. BMC Complementary and Alternative Medicine  (2015) 15:240 Page 11 of 11
